Molecular alterations characteristic of glioblastoma include the amplification of EGFR and the loss of the PTEN tumor suppressor, which lead to the constitutive activation of the PI3K/Akt pathway and provides the rationale for our focus in this Project on a unique PI3K inhibitor, PX-866 (ProIX). This wortmannin analog offers three key improvements: 1) it is biologically stable;2) it is a more potent inhibitor of the p110-a subunit of PI3K and 3) it is a weaker inhibitor of p110-p, and so shows much reduced dose limiting ontarget toxicity common to all PI3K inhibitors. We plan to test the hypothesis that the PI3K inhibitor PX- 866 is an effective therapy for glioma by evaluating it in preclinical models and in the clinic in early phase clinical trials for glioblastoma. However, the limited success of signal transduction inhibitors used as single agents, which is most likely due to compensatory or collateral pathways, is a strong rationale for exploring combination therapies. Some combinations can be suggested on the basis of current knowledge of signaling pathways, and we propose to test the most compelling in our models and the clinic. At the same time we plan to identify additional molecular target(s) or pathway(s) that would, once they are blocked by another drug, confer synergy to a PI3K inhibitor, based on siRNA synthetic lethality screening. Together these efforts will test the hypothesis that combination therapies based on PI3K inhibitors are effective in the treatment of glioma.
Our Specific Aims are 1) To study PX-866 and rational combinations in improved preclinical culture and animal models of glioma, using xenografts of human glioma cells that retain the molecular hallmarks of the parental tumors and on brain cancer stem cells. Rational combinations include PX-866 and the small molecule drugs Tarceva, Sorafenib and rapamycin/RADOOl as well as the standard of care - radiation and temozolomide;2) To initiate clinical trials of PX-866 and rational combinations, based on the data obtained in Aim 1;and 3) To identify novel synergistic targets for rational drug combinations with PX-866 using siRNA synthetic lethality screening. By completing these Aims we will pursue, in parallel, the clinical deployment of a promising PI3K inhibitor and the development of combination therapies based on it. Both rational (Aim 1) and newly discovered (Aim 3) co-targets/therapies will be developed, allowing both near-term and mid-term combination therapies to follow the individual lead compound (Aim 2) into clinical evaluation. Therefore this project emphasizes the translational dimension of our signal transduction research program with the hope of accelerating promising new treatment to the bedside.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127001-02
Application #
7921417
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
2
Fiscal Year
2009
Total Cost
$278,463
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Qianghu; Hu, Baoli; Hu, Xin et al. (2018) Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 33:152
Dong, Jianwen; Park, Soon Young; Nguyen, Nghi et al. (2018) The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. Oncotarget 9:10497-10509
Thomas, Jonathan G; Parker Kerrigan, Brittany C; Hossain, Anwar et al. (2018) Ionizing radiation augments glioma tropism of mesenchymal stem cells. J Neurosurg 128:287-295
Lu, Zhimin; Hunter, Tony (2018) Metabolic Kinases Moonlighting as Protein Kinases. Trends Biochem Sci 43:301-310
Jacobs, Daniel I; Liu, Yanhong; Gabrusiewicz, Konrad et al. (2018) Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol 136:33-39
Lu, Sean; Wang, Yugang (2018) Nonmetabolic functions of metabolic enzymes in cancer development. Cancer Commun (Lond) 38:63
Qiao, Yang; Gumin, Joy; MacLellan, Christopher J et al. (2018) Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection. Nanotechnology 29:165101
Zinn, Pascal O; Singh, Sanjay K; Kotrotsou, Aikaterini et al. (2018) A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res 24:6288-6299
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Mostovenko, Ekaterina; Végvári, Ákos; Rezeli, Melinda et al. (2018) Large Scale Identification of Variant Proteins in Glioma Stem Cells. ACS Chem Neurosci 9:73-79

Showing the most recent 10 out of 232 publications